踝关节骨折是创伤骨科常见骨折之一。通过引入加速康复外科(enhanced recovery after surgery,ERAS)理念,对围手术期处理措施进行全面优化,可以进一步提高患者诊疗效果。为规范ERAS临床路径在踝关节骨折中的应用,基于前期研究经验,以循...踝关节骨折是创伤骨科常见骨折之一。通过引入加速康复外科(enhanced recovery after surgery,ERAS)理念,对围手术期处理措施进行全面优化,可以进一步提高患者诊疗效果。为规范ERAS临床路径在踝关节骨折中的应用,基于前期研究经验,以循证医学证据为依据,经过全国专家组反复讨论,编制该专家共识,供全国创伤骨科医师在临床工作中参考。该共识适用于所有进行择期手术治疗的成人新鲜踝关节骨折患者。共识共包含25条推荐意见,就踝关节骨折患者急诊处理、术前准备、术中处理以及术后恢复进行了全面介绍。展开更多
背景与目的慢性阻塞性肺病(chronic obstructive pulmonary diseases, COPD)降低患者心肺功能,可导致患者围手术期风险增加。本研究拟探讨术前短期高强度肺康复训练对肺癌合并COPD患者肺功能及术后并发症的影响。方法分析2016年6月-2016...背景与目的慢性阻塞性肺病(chronic obstructive pulmonary diseases, COPD)降低患者心肺功能,可导致患者围手术期风险增加。本研究拟探讨术前短期高强度肺康复训练对肺癌合并COPD患者肺功能及术后并发症的影响。方法分析2016年6月-2016年12月101例肺癌合并COPD患者的临床资料,其中肺康复训练组43例,常规治疗组58例,比较两组患者肺功能、术后肺部并发症、住院时间等指标,同时比较肺康复训练组训练前后肺功能相关指标。结果两组患者术前一般资料及肺功能无显著差异,康复训练组住院时间更长[(17.23±4.18) d vs (14.41±4.03) d],但术后住院时间与常规治疗组无显著差异[(8.93±3.78) d vs (9.62±3.98) d],两组患者术后肺部感染[8例(18.6%) vs 17例(29.3%)]、肺不张[1例(2.3%) vs 1例(1.7%)]、呼吸衰竭[1例(2.3%) vs 2例(3.4%)]等无显著差异。肺康复训练组训练前后FEV_1[(2.06±0.45) L vs (2.15±0.45) L, P<0.001]、PEF[(4.32±0.90) L/s vs (5.15±1.05) L/s, P<0.001]、PCO_2[(42.42±2.79) mmHg vs (41.58±2.98) mmHg, P=0.009]改善明显,按亚组分析,康复训练后中-重度COPD亚组FEV_1[(0.16±0.05) L (8.6%) vs (0.06±0.05) L (2.8%)]增加值较轻度COPD亚组更明显。结论术前短期肺康复训练可改善肺癌合并COPD患者肺功能,其中中-重度COPD患者肺功能改善更明显。展开更多
Tillering in rice is one of the most important agronomic traits.Rice tiller development can be divided into two main processes: the formation of the axillary bud and its subsequent outgrowth.Several genes critical for...Tillering in rice is one of the most important agronomic traits.Rice tiller development can be divided into two main processes: the formation of the axillary bud and its subsequent outgrowth.Several genes critical for bud formation in rice have been identified by genetic studies;however,their molecular functions and relationships are still largely unknown.Here,we report that MONOCULM 1 (MOC1) and MONOCULM 3/ TILLERS ABSENT 1/STERILE AND REDUCED TILLERING 1 (MOC3/TAB1/SRT1),two vital regulators for tiller formation in rice,physically interact to regulate tiller bud outgrowth through upregulating the expression of FLORAL ORGAN NUMBER 1 (FON1),the homolog of CLAVATA1 in rice.We found that M0C3 is able to directly bind the promoter ofFONI and subsequently activate FON1 expression.MOC1 functions as a coactivator of MOC3,whereas it could not directly bind the FON1 promoter,and further activated FON1 expression in the presence of MOC3.Accordingly,FON1 is highly expressed at axillary meristems and shows remarkably decreased expression levels in mod and moc3 mutants.Loss-of-function mutants of FON1 exhibit normal bud formation but defective bud outgrowth and reduced tiller number.Collectively,these results shed light on a joint transcriptional regulatory mechanim by MOC1 and MOC3,and establish a new framework for the control of tiller bud formation and outgrowth.展开更多
复方氨基酸注射液是肠外营养中氮的来源,广泛应用于不能经胃肠道给予或经胃肠道给予不能满足其营养需求的患者,在营养治疗中起重要作用。但目前对于复方氨基酸注射液临床应用的指征、剂型、剂量、时机,国内并无系统的指南或共识。为了...复方氨基酸注射液是肠外营养中氮的来源,广泛应用于不能经胃肠道给予或经胃肠道给予不能满足其营养需求的患者,在营养治疗中起重要作用。但目前对于复方氨基酸注射液临床应用的指征、剂型、剂量、时机,国内并无系统的指南或共识。为了进一步规范复方氨基酸注射液的临床应用,中华医学会肠外肠内营养学分会(Chinese Society for Parenteral and Enteral Nutrition,CSPEN)及中国抗癌协会肿瘤营养专业委员会(Chinese Society of Nutritional Oncology,CSNO)组织全国专家,在系统性文献检索的基础上,参考美国肠外肠内营养学会(American Society for Parenteral and Enteral Nutrition,ASPEN)、欧洲临床营养和代谢学会(European Society for Clinical Nutrition and Metabolism,ESPEN)、CSPEN及CSNO指南,结合我国临床实践,经多次交流讨论,达成此共识。包括10条推荐意见,涉及不同患者的蛋白质需要量及氨基酸剂型选择。展开更多
Advanced intrahepatic cholangiocarcinoma(ICC)has a dismal prognosis.Here,we report the efficacy and safety of combining toripalimab,lenvatinib,and gemcitabine plus oxaliplatin(GEMOX)as first-line therapy for advanced ...Advanced intrahepatic cholangiocarcinoma(ICC)has a dismal prognosis.Here,we report the efficacy and safety of combining toripalimab,lenvatinib,and gemcitabine plus oxaliplatin(GEMOX)as first-line therapy for advanced ICC.Thirty patients with pathologically confirmed advanced ICC received intravenous gemcitabine(1 g/m2)on Days 1 and 8 and oxaliplatin(85 mg/m2)Q3W for six cycles along with intravenous toripalimab(240 mg)Q3W and oral lenvatinib(8 mg)once daily for one year.The expression of programmed death-ligand 1(PD-L1)and genetic status was investigated in paraffin-embedded tissues using immunohistochemistry and whole-exome sequencing(WES)analysis.The primary endpoint was the objective response rate(ORR).Secondary outcomes included safety,overall survival(OS),progression-free survival(PFS),disease control rate(DCR)and duration of response(DoR).As of July 1,2022,the median follow-up time was 23.5 months,and the ORR was 80%.Twenty-three patients achieved partial response,and one achieved complete response.Patients(21/30)with DNA damage response(DDR)-related gene mutations showed a higher ORR,while patients(14/30)with tumor area positivity≥1(PD-L1 staining)showed a trend of high ORR,but without significant difference.The median OS,PFS,and DoR were 22.5,10.2,and 11.0 months,respectively.The DCR was 93.3%.Further,56.7%of patients experienced manageable grade≥3 adverse events(AEs),commonly neutropenia(40.0%)and leukocytopenia(23.3%).In conclusion,toripalimab plus lenvatinib and GEMOX are promising first-line regimens for the treatment of advanced ICC.A phase-III,multicenter,double-blinded,randomized study to validate our findings was approved by the National Medical Products Administration(NMPA,No.2021LP01825).展开更多
文摘踝关节骨折是创伤骨科常见骨折之一。通过引入加速康复外科(enhanced recovery after surgery,ERAS)理念,对围手术期处理措施进行全面优化,可以进一步提高患者诊疗效果。为规范ERAS临床路径在踝关节骨折中的应用,基于前期研究经验,以循证医学证据为依据,经过全国专家组反复讨论,编制该专家共识,供全国创伤骨科医师在临床工作中参考。该共识适用于所有进行择期手术治疗的成人新鲜踝关节骨折患者。共识共包含25条推荐意见,就踝关节骨折患者急诊处理、术前准备、术中处理以及术后恢复进行了全面介绍。
文摘背景与目的慢性阻塞性肺病(chronic obstructive pulmonary diseases, COPD)降低患者心肺功能,可导致患者围手术期风险增加。本研究拟探讨术前短期高强度肺康复训练对肺癌合并COPD患者肺功能及术后并发症的影响。方法分析2016年6月-2016年12月101例肺癌合并COPD患者的临床资料,其中肺康复训练组43例,常规治疗组58例,比较两组患者肺功能、术后肺部并发症、住院时间等指标,同时比较肺康复训练组训练前后肺功能相关指标。结果两组患者术前一般资料及肺功能无显著差异,康复训练组住院时间更长[(17.23±4.18) d vs (14.41±4.03) d],但术后住院时间与常规治疗组无显著差异[(8.93±3.78) d vs (9.62±3.98) d],两组患者术后肺部感染[8例(18.6%) vs 17例(29.3%)]、肺不张[1例(2.3%) vs 1例(1.7%)]、呼吸衰竭[1例(2.3%) vs 2例(3.4%)]等无显著差异。肺康复训练组训练前后FEV_1[(2.06±0.45) L vs (2.15±0.45) L, P<0.001]、PEF[(4.32±0.90) L/s vs (5.15±1.05) L/s, P<0.001]、PCO_2[(42.42±2.79) mmHg vs (41.58±2.98) mmHg, P=0.009]改善明显,按亚组分析,康复训练后中-重度COPD亚组FEV_1[(0.16±0.05) L (8.6%) vs (0.06±0.05) L (2.8%)]增加值较轻度COPD亚组更明显。结论术前短期肺康复训练可改善肺癌合并COPD患者肺功能,其中中-重度COPD患者肺功能改善更明显。
基金supported by the grants from the National Natural Science Foundation of China (31788103,91635301).
文摘Tillering in rice is one of the most important agronomic traits.Rice tiller development can be divided into two main processes: the formation of the axillary bud and its subsequent outgrowth.Several genes critical for bud formation in rice have been identified by genetic studies;however,their molecular functions and relationships are still largely unknown.Here,we report that MONOCULM 1 (MOC1) and MONOCULM 3/ TILLERS ABSENT 1/STERILE AND REDUCED TILLERING 1 (MOC3/TAB1/SRT1),two vital regulators for tiller formation in rice,physically interact to regulate tiller bud outgrowth through upregulating the expression of FLORAL ORGAN NUMBER 1 (FON1),the homolog of CLAVATA1 in rice.We found that M0C3 is able to directly bind the promoter ofFONI and subsequently activate FON1 expression.MOC1 functions as a coactivator of MOC3,whereas it could not directly bind the FON1 promoter,and further activated FON1 expression in the presence of MOC3.Accordingly,FON1 is highly expressed at axillary meristems and shows remarkably decreased expression levels in mod and moc3 mutants.Loss-of-function mutants of FON1 exhibit normal bud formation but defective bud outgrowth and reduced tiller number.Collectively,these results shed light on a joint transcriptional regulatory mechanim by MOC1 and MOC3,and establish a new framework for the control of tiller bud formation and outgrowth.
文摘复方氨基酸注射液是肠外营养中氮的来源,广泛应用于不能经胃肠道给予或经胃肠道给予不能满足其营养需求的患者,在营养治疗中起重要作用。但目前对于复方氨基酸注射液临床应用的指征、剂型、剂量、时机,国内并无系统的指南或共识。为了进一步规范复方氨基酸注射液的临床应用,中华医学会肠外肠内营养学分会(Chinese Society for Parenteral and Enteral Nutrition,CSPEN)及中国抗癌协会肿瘤营养专业委员会(Chinese Society of Nutritional Oncology,CSNO)组织全国专家,在系统性文献检索的基础上,参考美国肠外肠内营养学会(American Society for Parenteral and Enteral Nutrition,ASPEN)、欧洲临床营养和代谢学会(European Society for Clinical Nutrition and Metabolism,ESPEN)、CSPEN及CSNO指南,结合我国临床实践,经多次交流讨论,达成此共识。包括10条推荐意见,涉及不同患者的蛋白质需要量及氨基酸剂型选择。
基金National Natural Science Foundation of China(81972232,81830102,82150004)Clinical Research Plan of SHDC(SHDC‑2020CR1003A,SHDC-2020CR1022B)+3 种基金National Key Research and Development Program of China(2019YFC1316000,2019YFC1315800,and 2019YFC1315802)the Key Disease Joint Research Program of Xuhui District(XHLHGG202103),the Clinical Medicine Research Pilot Project of Shanghai Medical School of Fudan University(2020,21DGF501035/00)the Shanghai Municipal Natural Science Foundation(20JC1419103,21ZR1412200)Beijing Mutual Care Public Welfare Foundation(GDXZ-08-05)Sanming Project of Medicine in Shenzhen(SZSM202003009),and Shanghai Municipal Key Clinical Specialty Construction Project(shslczdzk02401).
文摘Advanced intrahepatic cholangiocarcinoma(ICC)has a dismal prognosis.Here,we report the efficacy and safety of combining toripalimab,lenvatinib,and gemcitabine plus oxaliplatin(GEMOX)as first-line therapy for advanced ICC.Thirty patients with pathologically confirmed advanced ICC received intravenous gemcitabine(1 g/m2)on Days 1 and 8 and oxaliplatin(85 mg/m2)Q3W for six cycles along with intravenous toripalimab(240 mg)Q3W and oral lenvatinib(8 mg)once daily for one year.The expression of programmed death-ligand 1(PD-L1)and genetic status was investigated in paraffin-embedded tissues using immunohistochemistry and whole-exome sequencing(WES)analysis.The primary endpoint was the objective response rate(ORR).Secondary outcomes included safety,overall survival(OS),progression-free survival(PFS),disease control rate(DCR)and duration of response(DoR).As of July 1,2022,the median follow-up time was 23.5 months,and the ORR was 80%.Twenty-three patients achieved partial response,and one achieved complete response.Patients(21/30)with DNA damage response(DDR)-related gene mutations showed a higher ORR,while patients(14/30)with tumor area positivity≥1(PD-L1 staining)showed a trend of high ORR,but without significant difference.The median OS,PFS,and DoR were 22.5,10.2,and 11.0 months,respectively.The DCR was 93.3%.Further,56.7%of patients experienced manageable grade≥3 adverse events(AEs),commonly neutropenia(40.0%)and leukocytopenia(23.3%).In conclusion,toripalimab plus lenvatinib and GEMOX are promising first-line regimens for the treatment of advanced ICC.A phase-III,multicenter,double-blinded,randomized study to validate our findings was approved by the National Medical Products Administration(NMPA,No.2021LP01825).
